<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00335894</url>
  </required_header>
  <id_info>
    <org_study_id>04I/HMG10</org_study_id>
    <nct_id>NCT00335894</nct_id>
  </id_info>
  <brief_title>Clinical Study of Clinical Efficacy and Tolerability of hMG-IBSA s.c.in Women Undergoing COH in an ART Programme (IVF).</brief_title>
  <official_title>A Prospective, Randomized, Investigator-blind, Controlled, Clinical Study of Phase III on the Efficacy and Tolerability of hMG-IBSA (IBSA) vs Menopur (Ferring) Administered s.c. in Women Undergoing COH in an ART Programme (IVF)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>IBSA Institut Biochimique SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>IBSA Institut Biochimique SA</source>
  <brief_summary>
    <textblock>
      Multicenter, prospective, randomized, investigator blind, controlled clinical trial. Two
      parallel groups, one receiving the test drug hMG (hMG-IBSA, IBSA Institut Biochimique sa) and
      the other the reference drug hMG (Menopur, Ferring Pharmaceuticals, Inc.).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to evaluate the clinical efficacy and general tolerability of two
      different subcutaneous hMG preparations (hMG-IBSA, IBSA vs Menopur, Ferring Pharmaceuticals,
      Inc.) when administered to patients undergoing controlled ovarian stimulation for IVF.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date>March 2009</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single</masking>
  </study_design_info>
  <primary_outcome>
    <measure>total number of oocytes retrieved 34 - 36 hours after hCG administration.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total dose of hMG (IU); number of days of hMG stimulation and stimulation duration; cancellation rate with reasons; 17β-estradiol (E2) serum concentration; number of follicles &gt;16 mm.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of mature oocytes and inseminated oocytes; fertilization rate.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>embryo score; number of transferred embryos; implantation rate, number of transferred embryos; clinical pregnancy rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability evaluation</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Infertility</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hMG-IBSA</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women undergoing ovarian stimulation for IVF with or without ICSI (intracytoplasmic
             sperm injection) and with the following characteristics:

          -  Voluntary given informed consent to study participation in writing encompassing
             consent to data recording and verification procedures;

          -  &gt; 18/= and &lt; 37 years old;

          -  BMI between 18 and 28 kg/m2;

          -  Less than 3 previous completed IVF cycles;

          -  Basal FSH level less than 10 IU/L once within 6 months prior to the study;

          -  Within 12 month of the beginning of the study, uterine cavity consistent with expected
             normal function as assessed through a hysterosalpingogram, or sonohysterogram, or
             hysteroscopic examination or TVUS;

          -  Normal or clinically insignificant haematology and blood chemistry values.

        Exclusion Criteria:

          -  Primary ovarian failure or women known as poor responders;

          -  Signs of PCO, according to the Rotterdam Criteria;

          -  At least one ovary inaccessible for oocyte retrieval;

          -  One or more ovarian cysts &gt; 10 mm;

          -  Hydrosalpinx that have not been surgically removed or ligated;

          -  Stage III or IV endometriosis;

          -  Patients affected by pathologies associated with any contraindication of being
             pregnant;

          -  Hypersensitivity to the study medication;

          -  Abnormal bleeding of undetermined origin;

          -  Uncontrolled thyroid or adrenal dysfunction;

          -  Neoplasias;

          -  PAP smear III within the last 2 years;

          -  Severe impairment of the renal and/or hepatic functions;

          -  Lactation;

          -  Hyperprolactinaemia;

          -  Participation in a concurrent clinical trial or in another trial within the past four
             weeks;

          -  Use of concomitant medication that might interfere with study evaluations.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>36 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe De Placido, Prof</last_name>
    <role>Study Director</role>
    <affiliation>Federico II University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Università degli Studi di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Napoli Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Hauschke D, Kieser M, Diletti E, Burke M. Sample size determination for proving equivalence based on the ratio of two means for normally distributed data. Stat Med. 1999 Jan 15;18(1):93-105.</citation>
    <PMID>9990695</PMID>
  </reference>
  <reference>
    <citation>Veeck LL. Oocyte assessment and biological performance. Ann N Y Acad Sci. 1988;541:259-74.</citation>
    <PMID>3195909</PMID>
  </reference>
  <reference>
    <citation>GEMZELL CA, DICZFALUSY E, TILLINGER G. Clinical effect of human pituitary follicle-stimulating hormone (FSH). J Clin Endocrinol Metab. 1958 Dec;18(12):1333-48.</citation>
    <PMID>13611018</PMID>
  </reference>
  <reference>
    <citation>Filicori M, Cognigni GE, Pocognoli P, Tabarelli C, Ferlini F, Perri T, Parmegiani L. Comparison of controlled ovarian stimulation with human menopausal gonadotropin or recombinant follicle-stimulating hormone. Fertil Steril. 2003 Aug;80(2):390-7.</citation>
    <PMID>12909504</PMID>
  </reference>
  <reference>
    <citation>Kilani Z, Dakkak A, Ghunaim S, Cognigni GE, Tabarelli C, Parmegiani L, Filicori M. A prospective, randomized, controlled trial comparing highly purified hMG with recombinant FSH in women undergoing ICSI: ovarian response and clinical outcomes. Hum Reprod. 2003 Jun;18(6):1194-9.</citation>
    <PMID>12773445</PMID>
  </reference>
  <reference>
    <citation>Thompson CR, Hansen LM. Pergonal (menotropins): a summary of clinical experience in the induction of ovulation and pregnancy. Fertil Steril. 1970 Dec;21(12):844-53.</citation>
    <PMID>5481991</PMID>
  </reference>
  <reference>
    <citation>Oelsner G, Serr DM, Mashiach S, Blankstein J, Snyder M, Lunenfeld B. The study of induction of ovulation with menotropins: analysis of results of 1897 treatment cycles. Fertil Steril. 1978 Nov;30(5):538-44.</citation>
    <PMID>720642</PMID>
  </reference>
  <reference>
    <citation>Schwartz M, Jewelewicz R, Dyrenfurth I, Tropper P, Vande Wiele RL. The use of human menopausal and chorionic gonadotropins for induction of ovulation. Sixteen years' experience at the Sloane Hospital for Women. Am J Obstet Gynecol. 1980 Dec 1;138(7 Pt 1):801-7.</citation>
    <PMID>6778212</PMID>
  </reference>
  <reference>
    <citation>Notation AD, Tagatz GE, Steffes MW. Serum 17beta-estradiol. Index of follicular maturation during gonadotropin therapy. Obstet Gynecol. 1978 Feb;51(2):204-9.</citation>
    <PMID>622235</PMID>
  </reference>
  <reference>
    <citation>Mendelson EB, Bohm-Velez M, Joseph N, Neiman HL. Gynecologic imaging: comparison of transabdominal and transvaginal sonography. Radiology. 1988 Feb;166(2):321-4.</citation>
    <PMID>3275976</PMID>
  </reference>
  <reference>
    <citation>Vermesh M, Kletzky OA. Follicle-stimulating hormone is the main determinant of follicular recruitment and development in ovulation induction with human menopausal gonadotropin. Am J Obstet Gynecol. 1987 Dec;157(6):1397-402.</citation>
    <PMID>3122575</PMID>
  </reference>
  <reference>
    <citation>Brown JB, Evans JH, Adey FD, Taft HP, Townsend L. Factors involved in the induction of fertile ovulation with human gonadotrophins. J Obstet Gynaecol Br Commonw. 1969 Apr;76(4):289-307.</citation>
    <PMID>5778792</PMID>
  </reference>
  <reference>
    <citation>Venturoli S, Paradisi R, Fabbri R, Magrini O, Porcu E, Flamigni C. Comparison between human urinary follicle-stimulating hormone and human menopausal gonadotropin treatment in polycystic ovary. Obstet Gynecol. 1984 Jan;63(1):6-11.</citation>
    <PMID>6419189</PMID>
  </reference>
  <reference>
    <citation>Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv. 1989 Jun;44(6):430-40. Review.</citation>
    <PMID>2660037</PMID>
  </reference>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2006</study_first_submitted>
  <study_first_submitted_qc>June 9, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2006</study_first_posted>
  <last_update_submitted>March 9, 2010</last_update_submitted>
  <last_update_submitted_qc>March 9, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2010</last_update_posted>
  <keyword>Infertility</keyword>
  <keyword>IVF</keyword>
  <keyword>ART</keyword>
  <keyword>hMG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

